# AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

> **NCT00719524** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 71 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** OMBRABULIN (AVE8062)

## Key facts

- **NCT ID:** NCT00719524
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2013-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719524, "AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00719524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*